Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 January 2025 | Story Dr Nitha Ramnath | Photo Sonia Small
Prof Brownhilder Neneh
Prof Brownhilder Neneh stands out as an inspiring force for students and aspiring entrepreneurs.

In the dynamic intersection of tradition and innovation within academia, Prof Brownhilder Neneh, Vice-Dean: Research, Engagement and Internationalisation in the Faculty of Economic and Management Sciences at the University of the Free State (UFS), stands out as an inspiring force for students and aspiring entrepreneurs. Her remarkable career trajectory – ascending rapidly through the ranks from senior lecturer to head of department, and ultimately to full professor – has been marked not only by professional accolades, but by a deep, personal impact on the lives of her students and the broader entrepreneurial community. 

Personal moments of student connection  

Reflecting on her career, Prof Neneh’s achievements are impressive. “The best moment of my career is twofold,” she explains. “Professionally, I am incredibly grateful for the success I’ve achieved in less than a decade. Being promoted to professor, launching my book this year, and being consistently recognised as one of the top-cited researchers in the world over the past two years – it’s all been surreal.” 

However, it is the personal connections with her students that leave the most lasting impression. One student shared a heartfelt message, recalling how Prof Neneh’s encouragement helped her persevere through academic challenges. “You have everything it takes to succeed,” Prof Neneh had told her, transforming her outlook on her studies. Another student credited Prof Neneh’s words of encouragement with sparking a journey of self-acceptance, reminding her that “the best is yet to come.” These experiences highlight the profound influence of mentorship and the power of positive reinforcement. 

Building entrepreneurial competencies 

Prof Neneh’s research centres on fostering entrepreneurial skills, with a particular focus on youth and women. “I wish people knew that my work is about making a real, tangible difference,” she notes. Her research addresses the unique challenges faced by women entrepreneurs, including the complexities of work-life balance and societal pressures. By providing evidence-based strategies drawn from her extensive experience, Prof Neneh seeks to empower those navigating the intersection of family and business obligations. 

She also emphasises the obstacles facing young entrepreneurs, such as limited access to resources and a fear of failure. “These challenges can deter aspiring entrepreneurs from taking risks and pursuing their dreams,” Prof Nene says. Her approach to teaching entrepreneurship is rooted in practical, evidence based advice, encouraging aspiring entrepreneurs to pursue their passions, employ ‘effectual reasoning’ in building their ventures with available resources – and commit to lifelong learning. “Training doesn’t stop at obtaining a degree. It’s about continually seeking knowledge and adapting to the market,” she asserts. 

Prof Neneh also advocates collaboration through a concept she calls ‘coopetition’ – where competition fosters cooperation, particularly in overcoming resource constraints. This mindset has been especially valuable during times of crisis, such as the recent pandemic, when industries banded together for collective growth. 

For budding entrepreneurs, Prof Neneh offers a wealth of practical advice. She stresses the importance of validating the market before launching a business, while cautioning against entering fields devoid of passion or thorough preparation. Her guiding principle? “Invest wisely and understand the needs of your target market.” 

Creating ripples of positive impact 

Looking ahead, Prof Neneh embodies resilience. “I wouldn’t change anything in my life. Every challenge has been a lesson,” she reflects. Her experiences have not only shaped her career, but also strengthened her sense of purpose. “Stay true to your values and purpose,” is the advice she follows, ensuring her life’s work continues to create ripples of positive impact. 

Prof Neneh is not only an academic; she is a champion for change, dedicated to uplifting others through her research, mentorship, and community initiatives such as ‘She Believe’, a peer support group focused on empowering women. As she continues to inspire future generations, her story serves as a powerful reminder that the entrepreneurial journey is not merely about financial success – it is about transformative impact and demonstrating resilience. 

The belief that “the best is yet to come” resonates not only in Prof Neneh’s life, but also with everyone who has the privilege of learning from her.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept